Ich Quality Guidelines
Editat de Andrew Teasdale, David Elder, Raymond W Nimsen Limba Engleză Hardback – 9 oct 2017
Preț: 1984.65 lei
Preț vechi: 2180.93 lei
-9%
Puncte Express: 2977
Preț estimativ în valută:
350.98€ • 411.87$ • 304.42£
350.98€ • 411.87$ • 304.42£
Carte tipărită la comandă
Livrare economică 09-23 martie
Specificații
ISBN-13: 9781118971116
ISBN-10: 1118971116
Pagini: 736
Dimensiuni: 157 x 235 x 44 mm
Greutate: 1.2 kg
Editura: Wiley
Locul publicării:Hoboken, United States
ISBN-10: 1118971116
Pagini: 736
Dimensiuni: 157 x 235 x 44 mm
Greutate: 1.2 kg
Editura: Wiley
Locul publicării:Hoboken, United States
Public țintă
Pharma and biotech drug industry personnel: chemists, analytical testing, quality assurance, regulatory affairs, formulations, manufacturing, legal, R&D and marketingGovernment and regulatory agencies
Chemical, pharmaceutical, and medical libraries
Academics who teach pharmaceutics, analytic development and drug development
Notă biografică
Andrew Teasdale, PhD, is a principal scientist in pharmaceutical development with AstraZeneca. He has over 20 years' experience within the industry and has held a number of leadership roles both internally and externally at a cross industry level encompassing key ICH topic areas. David Elder, PhD, is an independent CMC consultant. He has 40 years' experience within the pharmaceutical industry. He was formerly a director within GlaxoSmithKline's platform technology and science function. He is an expert member for the British Pharmacopoeia and has extensive CMC experience encompassing many of the key ICH topics. Raymond W. Nims, PhD, is a Senior Consultant at RMC Pharmaceutical Solutions, with experience in a variety of GMP quality assurance and quality control topics from a biologics point of reference. He has served on ad hoc panels supporting a number of USP chapters and ANSI Standards.
Descriere
Examining the implications and practical implementation of multi-disciplinary International Conference on Harmonization (ICH) topics, this book gives an integrated view of how the guidelines inform drug development strategic planning and decision-making, together with impact on marketed products.